Interactome Yields Data, But Is It Significant?

FEATUREHuman Interactome Project Interactome Yields Data, But Is It Significant? An investment of $100 million should be enough to correlate the genome with function, and identify new basic research and drug targets BY JEFFREY M. PERKELARTICLE EXTRASRelated Articles: Time for a Human Interactome Project?An investment of $100 million should be enough to correlate the genome with function, and identify new

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

An investment of $100 million should be enough to correlate the genome with function, and identify new basic research and drug targets

The first human interactome maps, published just last year, offer literally thousands of starting points for further research.1,2 Yet subsequent analyses also demonstrate just how difficult it can be to convert interaction data into reliable hypotheses.

Both Marc Vidal and Erich Wanker, who published his map first, used their data to identify novel interactions. For example, Wanker identified new partners for the protein emerin, a mutation that leads to Emery-Dreifuss muscular dystrophy, as well as novel modulators of the Wnt signaling pathway. Vidal identified 424 interaction pairs in which at least one member had previously been implicated in human disease, including a new interaction between RTN4, a neurite outgrowth inhibitor, and SPG21 (spastic paraplegia 21), a mutation that leads to Mast syndrome.

In January Peter Uetz, Yu-An Dong, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Jeffrey M. Perkel

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio